BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
Pharmaceuticals, Biotechnology and Life Sciences
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period…
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period…
DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative…
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced…
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform…
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash…
Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial…
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…